The expansion, which will provide aseptic filling capacity for the production of both cytotoxic and non-cytotoxic drugs for Phase I and II clinical trials, is expected to be fully completed and operational in the next few months.
Earlier this month the European arm of US investment group Sun Capital Partners announced plans to buy the contract manufacturing organisation (CMO), citing its significant growth potential as a key driver for the move.
Speaking to Outsourcing-Pharma.com at the time NextPharma CEO Bill Wedlake said that the firm’s new owners would support both existing capacity expansion plans and help it grow through acquisitions.